Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06911931 · ClinicalTrials.gov registry record · NA

Visual Perception in Schizophrenia

A NA study of Bipolar Disorder and Schizoaffective Disorder, sponsored by University of Rochester.

Recruiting
Registry status
NA
Development phase
84
Enrollment target
1
Study location

NCT06911931: Recruiting NA study of Bipolar Disorder and Schizoaffective Disorder, sponsored by University of Rochester.

NCT06911931 is a NA study of Bipolar Disorder and Schizoaffective Disorder that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 84 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06911931, a NA study of Bipolar Disorder and Schizoaffective Disorder, is actively recruiting participants, sponsored by University of Rochester.

RECRUITING
Registry status
NA
Development phase
84 participants
Enrollment target
1
Study location

Study Summary

This study aims to identify novel markers of psychosis using electroencephalography (EEG).

Interventions

  • OTHER EEG measure of visual processing

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2025-11-03
Est. Completion 2027-01-31
Phase NA
University of Rochester

636 total trials

What NCT06911931 shows while recruiting

NCT06911931 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (75% lower).

The record links to 3 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which EEG measure of visual processing is the first listed.

NCT06911931 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06911931 about?

NCT06911931 is a clinical study titled "Visual Perception in Schizophrenia". This study aims to identify novel markers of psychosis using electroencephalography (EEG).

What is the current status of trial NCT06911931?

This trial is currently recruiting. It is a NA study. The enrollment target is 84 participants. The study started on 2025-11-03. Estimated completion is 2027-01-31.

What conditions does trial NCT06911931 study?

This clinical trial studies the following conditions: Bipolar Disorder, Schizoaffective Disorder, Schizophrenia Disorders.

What interventions are being tested in trial NCT06911931?

The interventions under investigation include: EEG measure of visual processing (OTHER).

Who is sponsoring clinical trial NCT06911931?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06911931 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bipolar Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06911931's enrollment target sits among peer trials

84 75th of 162 higher than 88 of 162 other Bipolar Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02391519 · 84 participants

    Effects of High Altitude on AMPK Activation

  • NCT03838536 · 84 participants · NA

    Synergistic Activity of Human Milk Nutrients and Infant Cognition

  • NCT03884075 · 84 participants · Phase 2

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

  • NCT03894917 · 84 participants

    Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06911931, the US trial registry maintained by the National Library of Medicine. NCT06911931 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.